Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

@article{Mendel2000DevelopmentOS,
  title={Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.},
  author={Dirk B. Mendel and A. Douglas Laird and Beverly D Smolich and Robert AL Blake and Congxin Liang and Alison L. Hannah and Raymond M. Shaheen and Lee M. Ellis and Steve Weitman and Laura K. Shawver and Julie M. Cherrington},
  journal={Anti-cancer drug design},
  year={2000},
  volume={15 1},
  pages={29-41}
}
Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 100 extracted citations

Angiogenesis inhibitors in the treatment of prostate cancer.

Expert opinion on pharmacotherapy • 2010
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…